Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Asian Markets Retreat as Gulf Crisis Fuels Oil Surge and Inflation Fears
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
U.S. Natural Gas Market Faces Short-Term Pressure but Long-Term Demand Surge
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Oil Prices Rebound as Hormuz Disruptions and Middle East Tensions Rattle Markets
Bank of Japan Governor Signals Accommodative Stance Amid Negative Real Rates
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Trump Claims Oil Tankers Heading to U.S. Amid Iran War and Strait of Hormuz Crisis
Middle East Conflict Threatens Global Economic Stability, World Bank Warns
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Asia FX Weekly Gains Hold Amid U.S. Inflation Data and Iran Ceasefire Uncertainty 



